Cinda Biotech (01801) announced interim results. Profit of 1,253 billion yuan increased 50.2% year-on-year

According to Zhitong Finance App News, Cinda Biotech (01801) announced interim results for the six months ended June 30, 2026, measured according to International Financial Reporting Standards (IFRS): total revenue of 8.618 billion yuan (RMB, same below), up 44.8% year on year; profit for the period was 1,253 billion yuan, up 50.2% year on year; basic income per share was 0.73 yuan.

According to the announcement, in the first half of 2026, the company's revenue grew rapidly, the scale of profits continued to expand, cash on hand was abundant, many large-scale international partnerships were implemented, and more pipelines showed global value — these solid developments give us reason to believe that Cinda Biotech is in the best development window since its establishment. On this basis, in the next five to ten years, we hope to complete the third key transformation — from a leading local biopharmaceutical company to a world-class biopharmaceutical company with initial multinational operating capabilities.

Our commercial product portfolio includes 20 approved products: Dabershu® (Cindilizumab injection), Dayoutong® (bevacizumab injection), Sulisin® (adalimumab injection), dabroximab® (rituximab injection), dabertan® (pemitinib tablets), Nellick® (olevatinib tablets), Shiranze® (ramucilizumab), Ruituo® (ceptinib capsules), and fukosu (ilentinil) (Cystel injection), Cipilac® (tolecimab injection), Dabert® (fluzelacide tablets), Dabol® (tarretinib adipate capsules), Dabol® (taretinib adipate capsules), Jepa Force® (pitobutinib tablets), Olexin® (liotinib tablets), Cinpimin® (teituximab N01 injection), Xinermei® (mashidopeptide injection), XinmeiYue® (picontibimab injection), daboxin® (ipimumab N01 injection), WeizeXIN® (abecilil tablets), and vivoxil® (quizatinib hydrochloride tablets). 13 of our products have been included in the NRDL.

In the first half of 2026, the company achieved total revenue of RMB 8.618 billion and product revenue of RMB 8.202 billion, an increase of 44.8% and 56.7%, respectively. This strong performance is due to the effective implementation of the company's dual-engine growth strategy, the accelerated release of integrated pipeline business contributions, and the continuous release of new oncology pipeline products included in the National Medical Insurance Drug List (NRDL).

As measured by IFRS, net profit increased 50.2% year over year to RMB 1,253 billion; non-IFRS net profit increased 40.5% year over year to reach RMB 1,704 billion. Strong profit growth was mainly due to rapid revenue release and continuous improvement in operating efficiency.

The operating results of the first half of 2026 not only confirm that the company's business trend continues to improve, but also mark that the company has entered a new stage of simultaneous improvement in revenue and profit quality, and is making steady progress towards the goal of becoming a “world-class biopharmaceutical company”.